Nutrition and cancer /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Buqu�e, Aitziber (Editor ), Galluzzi, Lorenzo (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2022.
Colección:International review of cell and molecular biology ; v. 373.
Temas:
Cancer > Nutritional aspects.
Cancer > Cytopathology.
Cancer > Aspect nutritionnel.
Cancer > Cytopathologie.
Cancer > Cytopathology
Cancer > Nutritional aspects
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Nutrition and Cancer
  • Copyright
  • Contents
  • Contributors
  • Emergent impact of lifestyle on tumor progression and response to therapy
  • Acknowledgments
  • Conflict of interest
  • References
  • Chapter One: Modifying dietary amino acids in cancer patients
  • 1. Introduction
  • 2. Reducing availability of NEAAs as an anti-cancer approach
  • 3. Role of essential AAs in cancer biology
  • 4. Altering dietary protein to limit tumor growth and enhance cancer therapy
  • 5. Role of bacteria in mediating the pro-tumorigenic effects of dietary AAs
  • 6. Current recommendations for protein intake in cancer patients
  • 7. Considerations for evaluating the impact of modifying AA intake on treatment response and outcomes in patients with cancer
  • Acknowledgments
  • Conflicts of interest
  • References
  • Chapter Two: Targeting amino acid metabolism in cancer
  • 1. Introduction
  • 2. Asparagine
  • 2.1. Asparagine synthetase (ASNS)
  • 2.1.1. Catalytic function and structure of ASNS
  • 2.1.2. ASNS deficiency
  • 2.1.3. ASNS regulation
  • 2.2. L-asparaginase (ASNase)
  • 2.2.1. ASNase in leukemias and lymphomas
  • 2.2.2. ASNase in solid tumors
  • 2.2.3. Glutaminase activity of ASNase
  • 2.2.4. Limits of the ASNase therapy
  • 3. Arginine
  • 3.1. Metabolism of arginine
  • 3.2. Arginine-nitric oxide pathway
  • 3.3. Arginine-ornithine-polyamine pathway
  • 3.4. Suitable candidates for arginine-depleting enzyme therapies
  • 3.5. Arginine deiminase
  • 3.5.1. Arginine deiminase-based therapy
  • 3.5.2. Limitations of arginine deiminase therapy
  • 3.6. Arginase
  • 3.6.1. Arginase therapy
  • 3.6.2. Limitations of arginase therapy
  • 4. Methionine
  • 4.1. Methionine metabolism
  • 4.2. The Hoffman effect
  • 4.3. Methioninase
  • 4.3.1. Methioninase therapy
  • 5. Cysteine
  • 5.1. Cysteine metabolism
  • 5.2. Cyst(e)inase
  • 5.2.1. Cyst(e)inase therapy
  • 6. Concluding remarks
  • Acknowledgments
  • References
  • Chapter Three: Fasting and cancer: from yeast to mammals
  • 1. Introduction
  • 2. Calorie restriction
  • 3. Fasting and fasting mimicking diets
  • 4. Fasting mimicking diets and cancer
  • 4.1. Differential stress resistance
  • 4.2. Differential stress sensitization
  • 4.3. FMD and antitumor immunity
  • 5. Fasting-mimicking diets and non-toxic interventions to kill cancer cells
  • 5.1. FMD synergizes with high-dose vitamin C to kill KRAS-mutant cancer cells
  • 5.2. FMD cycles potentiate hormone therapies and induce breast cancer regression
  • 6. Fasting-mimicking diets in clinical oncology
  • Acknowledgments
  • References
  • Chapter Four: Fasting and cancer responses to therapy
  • 1. Introduction
  • 2. Nutrients restriction in rodents and humans
  • 3. Calorie restriction in cancer therapy
  • 4. Alternative approaches to fasting and CR in cancer therapy
  • 5. Conclusion
  • Acknowledgments
  • Conflicts of interest
  • Authors contribution
  • References

Ejemplares similares